K
Kirk N. Campbell
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 80
Citations - 3071
Kirk N. Campbell is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Podocyte & Focal segmental glomerulosclerosis. The author has an hindex of 21, co-authored 59 publications receiving 2354 citations. Previous affiliations of Kirk N. Campbell include University of Miami & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
Christian Faul,Mary Donnelly,Mary Donnelly,Sandra Merscher-Gomez,Sandra Merscher-Gomez,Yoon Hee Chang,Yoon Hee Chang,Stefan Franz,Stefan Franz,Jacqueline Delfgaauw,Jacqueline Delfgaauw,Jer Ming Chang,Hoon Young Choi,Kirk N. Campbell,Kirk N. Campbell,Kwanghee Kim,Jochen Reiser,Jochen Reiser,Peter Mundel,Peter Mundel +19 more
TL;DR: It is shown that the beneficial effect of CsA on proteinuria is not dependent on NFAT inhibition in T cells, but rather results from the stabilization of the actin cytoskeleton in kidney podocytes, preserving the phosphorylation-dependent synaptopodin–14-3-3β interaction.
Journal ArticleDOI
Abatacept in B7-1–Positive Proteinuric Kidney Disease
Chih Chuan Yu,Chih Chuan Yu,Alessia Fornoni,Astrid Weins,Samy Hakroush,Dony Maiguel,Junichiro Sageshima,Linda Chen,Gaetano Ciancio,Mohd Hafeez Faridi,Daniel Behr,Kirk N. Campbell,Jer Ming Chang,Hung Chun Chen,Jun Oh,Christian Faul,M. Amin Arnaout,Paolo Fiorina,Vineet Gupta,Anna Greka,George W. Burke,Peter Mundel +21 more
TL;DR: Data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.
Journal ArticleDOI
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids
Jonas Sieber,Maja T. Lindenmeyer,Kapil Kampe,Kirk N. Campbell,Clemens D. Cohen,Helmut Hopfer,Peter Mundel,Andreas W. Jehle,Andreas W. Jehle +8 more
TL;DR: It is shown that palmitic acid increases podocyte cell death, both apoptosis and necrosis of podocytes, in a dose and time-dependent fashion and offers a rationale for interventional studies aimed at testing whether dietary shifting of the FFA balance toward unsaturated FFAs can delay the progression of DN.
Journal ArticleDOI
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Howard Trachtman,Peter T. Nelson,Sharon G. Adler,Kirk N. Campbell,Abanti Chaudhuri,Vimal K. Derebail,Giovanni Gambaro,Loreto Gesualdo,Debbie S. Gipson,Jonathan J. Hogan,Kenneth Lieberman,Brad Marder,Kevin E.C. Meyers,Kevin E.C. Meyers,Esmat Mustafa,Jai Radhakrishnan,Tarak Srivastava,Tarak Srivastava,Miganush Stepanians,Vladimir Tesar,Olga Zhdanova,Radko Komers +21 more
TL;DR: Patients with FSGS achieved significantly greater reductions in proteinuria after 8 weeks of sparsentan versus irbesartan, and eGFR was stable with both treatments.
Journal ArticleDOI
Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap
Youngmin A. Lee,Youngmin A. Lee,Luke A. Noon,Kemal M. Akat,Maria D. Ybanez,Ting Fang Lee,Marie-Luise Berres,Marie-Luise Berres,Naoto Fujiwara,Naoto Fujiwara,Nicolas Goossens,Nicolas Goossens,Hsin I. Chou,Fatemeh P. Parvin-Nejad,Bilon Khambu,Elisabeth G. Kramer,Ronald E. Gordon,Cathie M. Pfleger,Doris Germain,Gareth R. John,Kirk N. Campbell,Zhenyu Yue,Xiao Ming Yin,Ana Maria Cuervo,Mark J. Czaja,M. Isabel Fiel,Yujin Hoshida,Yujin Hoshida,Scott L. Friedman +28 more
TL;DR: It is shown that hepatocyte-specific loss of Atg7 in mice leads to decreased autophagic degradation of Yap and liver overgrowth, and this association in human liver cancer tissues is established, shedding new light on mechanisms of YAP degradation and the sequence of events that follow disruption of autophagy.